{"disease":{"id":"platinum-resistant-recurrent-ovarian-cancer","name":"platinum resistant recurrent ovarian cancer"},"drugs":{"marketed":[{"drug_id":"bevacizumab-maly","indication_name":"Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ALYMSYS","generic_name":"BEVACIZUMAB-MALY","company_name":"AMNEAL PHARMS LLC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04348032","title":"Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":152,"lead_sponsor_name":"Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT06434610","title":"A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Shanghai Jiaolian Drug Research and Development Co., Ltd","has_results":false},{"nct_id":"NCT03907527","title":"Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":71,"lead_sponsor_name":"Precigen, Inc","has_results":false},{"nct_id":"NCT02298959","title":"Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":59,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01970722","title":"Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT07462468","title":"A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer.","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":36,"lead_sponsor_name":"WestVac Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT04720807","title":"Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT07314619","title":"Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"The First Affiliated Hospital of Zhengzhou University","has_results":false},{"nct_id":"NCT03449108","title":"LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03508570","title":"Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06321484","title":"Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT03610490","title":"Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":16,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT05130515","title":"Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT03642990","title":"NR in Chemo-induced Peripheral Neuropathy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Donna Hammond, PhD","has_results":true}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}